Shopping Cart
Remove All
Your shopping cart is currently empty
Suvizumab (KD-247) is a humanized monoclonal neutralizing antibody targeting the V3 loop of the HIV-1 envelope glycoprotein gp120. This product specifically binds to the V3 domain of gp120, effectively neutralizing various HIV-1 strains (e.g., MN, SF2, and 89.6) and blocking virus-host cell fusion. Suvizumab reduces viral load and is well-tolerated, serving as an important pharmacological tool for researching HIV prevention, passive immunotherapy, and viral immune escape mechanisms.
| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 1 mg | $247 | 2-4 weeks | 2-4 weeks | |
| 5 mg | $697 | 2-4 weeks | 2-4 weeks | |
| 10 mg | $1,080 | 2-4 weeks | 2-4 weeks |
| Description | Suvizumab (KD-247) is a humanized monoclonal neutralizing antibody targeting the V3 loop of the HIV-1 envelope glycoprotein gp120. This product specifically binds to the V3 domain of gp120, effectively neutralizing various HIV-1 strains (e.g., MN, SF2, and 89.6) and blocking virus-host cell fusion. Suvizumab reduces viral load and is well-tolerated, serving as an important pharmacological tool for researching HIV prevention, passive immunotherapy, and viral immune escape mechanisms. |
| Targets&IC50 | HIV-1 SF2:1.0 μg/mL, HIV-1 MN:0.1 µg/mL, HIV-1 89.6:0.2 µg/mL |
| In vitro | In neutralization assays, Suvizumab (KD-247) demonstrates potent activity against multiple HIV-1 strains, with IC50 values of 0.1 µg/mL for HIV-1MN, 0.2 µg/mL for HIV-189.6, and 1.0 µg/mL for HIV-1SF2; however, the antibody shows significant resistance to pseudoviruses carrying the G314E mutation within the V3 loop [2][3]. |
| In vivo | In pharmacological studies using cynomolgus macaque models infected with SHIV C2/1, intravenous administration of Suvizumab (15, 30, and 45 mg/kg) dose-dependently reduced plasma viremia and increased CD4+ T-cell counts; furthermore, repeated weekly doses (45 mg/kg) for two months significantly mitigated the loss of CD4+ T cells in lymphoid tissues and provided sterile protection against viral challenge [2][4]. |
| Synonyms | KD-247 |
| Reactivity | Human |
| Application | FACS Functional assay |
| Antibody Type | Monoclonal |
| Formulation | Supplied as a sterile solution in a buffered formulation system (e.g., phosphate-, citrate-, or amino acid-based). Please refer to the CoA for lot-specific composition. |
| Endotoxin | <1.0 EU/mg |
| Conjucates | Unconjugated |
| Target | HIV-1 MN/HIV-1 SF2/HIV-1 89.6 |
| Cas No. | 914257-21-9 |
| Isotype | IgG1 |
| Storage | store at low temperature | store at -20°C | Shipping with blue ice/Shipping at ambient temperature. |
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.